Taken together, these results suggest a molecular basis for IPF resulting from a POT1 variant and pave the way for potential gene therapies seeking to exchange mutant POT1(L259S) for POT1(WT) or interventional drugs seeking to increase POT1 functionality. Here, POT1 is linked to idiopathic pulmonary fibrosis.